{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T18:00:02Z","timestamp":1790964002544,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2008,5,26]],"date-time":"2008-05-26T00:00:00Z","timestamp":1211760000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1007\/s10549-008-0056-8","type":"journal-article","created":{"date-parts":[[2008,5,25]],"date-time":"2008-05-25T17:28:58Z","timestamp":1211736538000},"page":"1-5","source":"Crossref","is-referenced-by-count":7,"title":["An association between invasive breast cancer and familial idiopathic hyperparathyroidism: a case series and review of the literature"],"prefix":"10.1007","volume":"115","author":[{"given":"Sumanta Kumar","family":"Pal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Blazer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Weitzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Somlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,5,26]]},"reference":[{"issue":"5","key":"56_CR1","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1053\/bbmt.2001.v7.pm11400951","volume":"7","author":"G Somlo","year":"2001","unstructured":"Somlo G, Chow W, Hamasaki V et al (2001) Tandem-cycle high-dose melphalan and cisplatin with peripheral blood progenitor cell support in patients with breast cancer and other malignancies. Biol Blood Marrow Transplant 7(5):284\u2013293. doi: 10.1053\/bbmt.2001.v7.pm11400951","journal-title":"Biol Blood Marrow Transplant"},{"key":"56_CR2","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3322\/canjclin.56.2.106","volume":"56","author":"A Jemal","year":"2006","unstructured":"Jemal A, Siegel R, Ward E et al (2006) Cancer statistics, 2006. CA Cancer J Clin 56:106\u2013130","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"56_CR3","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1056\/NEJM198001243020402","volume":"302","author":"H Heath","year":"1980","unstructured":"Heath H, Hodgson SF, Kennedy MA (1980) Primary hyperparathyroidism incidence, morbidity and potential economic impact in the community. N Engl J Med 302(4):189\u2013193","journal-title":"N Engl J Med"},{"issue":"5","key":"56_CR4","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nrc1610","volume":"5","author":"SJ Marx","year":"2005","unstructured":"Marx SJ (2005) Molecular genetics of multiple endocrine neoplasia types 1 and 2. Nat Rev Cancer 5(5):367\u2013375. doi: 10.1038\/nrc1610","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"56_CR5","doi-asserted-by":"crossref","first-page":"4929","DOI":"10.1158\/0008-5472.CAN-05-4461","volume":"66","author":"KM Dreijerink","year":"2006","unstructured":"Dreijerink KM, Mulder KW, Winkler GS et al (2006) Menin links estrogen receptor activation to histone H3K4 trimethylation. Cancer Res 66(9):4929\u20134935. doi: 10.1158\/0008-5472.CAN-05-4461","journal-title":"Cancer Res"},{"issue":"1","key":"56_CR6","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10549-005-9041-7","volume":"96","author":"MD Corte","year":"2006","unstructured":"Corte MD, Tamargo F, Alvarez A et al (2006) Cytosolic levels of TFF1\/pS2 in breast cancer: their relationship to clinical-pathological parameters and their prognostic significance. Breast Cancer Res Treat 96(1):63\u201372. doi: 10.1007\/s10549-005-9041-7","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"56_CR7","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cancergencyto.2007.08.009","volume":"179","author":"P Ghataorhe","year":"2007","unstructured":"Ghataorhe P, Kurian AW, Pickart A et al (2007) A carrier of both MEN1 and BRCA2 mutations: case report and review of the literature. Cancer Genet Cytogenet 179(2):89\u201392. doi: 10.1016\/j.cancergencyto.2007.08.009","journal-title":"Cancer Genet Cytogenet"},{"key":"56_CR8","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1046\/j.1365-2265.1998.00354.x","volume":"48","author":"K Yoshimoto","year":"1998","unstructured":"Yoshimoto K, Endo H, Tsuyuguchi M et al (1998) Familial isolated primary hyperparathyroidism with parathyroid carcinomas: clinical and molecular features. Clin Endocrinol (Oxf) 48:67\u201372. doi: 10.1046\/j.1365-2265.1998.00354.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"56_CR9","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1136\/jmg.2003.016725","volume":"41","author":"J Warner","year":"2004","unstructured":"Warner J, Epstein M, Sweet A et al (2004) Genetic testing in familial isolated hyperparathyroidism: unexpected results and their implications. J Med Genet 41(3):155\u2013160. doi: 10.1136\/jmg.2003.016725","journal-title":"J Med Genet"},{"issue":"2","key":"56_CR10","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/01.GIM.0000153663.62300.F8","volume":"7","author":"RD Klein","year":"2005","unstructured":"Klein RD, Salih S, Bessoni J et al (2005) Clinical testing for multiple endocrine neoplasia type 1 in a DNA diagnostic laboratory. Genet Med 7(2):131\u2013138. doi: 10.1097\/01.GIM.0000153663.62300.F8","journal-title":"Genet Med"},{"issue":"1","key":"56_CR11","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1677\/erc.1.01261","volume":"14","author":"IL Nilsson","year":"2007","unstructured":"Nilsson IL, Zedenius J, Yin L et al (2007) The association between primary hyperparathyroidism and malignancy: nationwide cohort on cancer incidence after parathyroidectomy. Endocr Relat Cancer 14(1):135\u2013140. doi: 10.1677\/erc.1.01261","journal-title":"Endocr Relat Cancer"},{"issue":"5","key":"56_CR12","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/BF03343867","volume":"24","author":"P Fierabracci","year":"2001","unstructured":"Fierabracci P, Pinchera A, Miccoli P et al (2001) Increased prevalence of primary hyperparathyroidism in treated breast cancer. J Endocrinol Invest 24(5):315\u2013320","journal-title":"J Endocrinol Invest"},{"issue":"7","key":"56_CR13","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1002\/1097-0142(19871001)60:7<1620::AID-CNCR2820600733>3.0.CO;2-3","volume":"60","author":"DM Axelrod","year":"1987","unstructured":"Axelrod DM, Bockman RS, Wong GY et al (1987) Distinguishing features of primary hyperparathyroidism in patients with breast cancer. Cancer 60(7):1620\u20131624. doi:10.1002\/1097-0142(19871001)60:7\u22641620::AID-CNCR2820600733\u22653.0.CO;2-3","journal-title":"Cancer"},{"issue":"9","key":"56_CR14","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1002\/1097-0142(19891101)64:9<1965::AID-CNCR2820640933>3.0.CO;2-G","volume":"64","author":"B Kristensen","year":"1989","unstructured":"Kristensen B, Mouridsen HT, Holmegaard SN et al (1989) Amelioration of postmenopausal primary hyperparathyroidism during adjuvant tamoxifen for breast cancer. Cancer 64(9):1965\u20131967. doi:10.1002\/1097-0142(19891101)64:9\u22641965::AID-CNCR2820640933\u22653.0.CO;2-G","journal-title":"Cancer"},{"key":"56_CR15","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s10552-007-9001-0","volume":"18","author":"M Almquist","year":"2007","unstructured":"Almquist M, Manjer J, Bondeson L et al (2007) Serum calcium and breast cancer risk: results form a prospective cohort study of 7,847 women. Cancer Causes Control 18:595\u2013602. doi: 10.1007\/s10552-007-9001-0","journal-title":"Cancer Causes Control"},{"key":"56_CR16","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/bjc.1995.282","volume":"721","author":"MA Birch","year":"1995","unstructured":"Birch MA, Carron JA, Scott M et al (1995) Parathryoid hormone (PTH)\/PTH-related protein (PTHrP) receptor expression and mitogenic responses in human breast cancer cell lines. Br J Cancer 721:90\u201395","journal-title":"Br J Cancer"},{"key":"56_CR17","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/sj.bjc.6600757","volume":"884","author":"RP Hoey","year":"2003","unstructured":"Hoey RP, Sanderson C, Iddon J et al (2003) The parathyroid-hormone related protein receptor is expressed in bone metastases and promotes autocrine proliferation of breast cancer cells. Br J Cancer 884:567\u2013573. doi: 10.1038\/sj.bjc.6600757","journal-title":"Br J Cancer"},{"key":"56_CR18","unstructured":"Bianchi GV, Loibl S, Zamagni C et\u00a0al (2007) Phase II multicenter trial of sorafenib in the treatment of patients with metastatic breast cancer. Proc Amer Soc Clin Oncol Breast Cancer Symposium 2007 (Abstract #164)"},{"issue":"24","key":"56_CR19","doi-asserted-by":"crossref","first-page":"11851","DOI":"10.1158\/0008-5472.CAN-06-1377","volume":"66","author":"L Liu","year":"2006","unstructured":"Liu L, Cao Y, Chen C et al (2006) Sorafenib blocks the RAF\/MEK\/ERK pathway, inhibits tumor angiogenesis and induces tumor cell apoptosis in hepatocellular carcinoma model PLC\/PRF\/5. Cancer Res 66(24):11851\u201311858. doi: 10.1158\/0008-5472.CAN-06-1377","journal-title":"Cancer Res"},{"key":"56_CR20","doi-asserted-by":"crossref","unstructured":"Nishioka C, Ikeoze T, Yang J et\u00a0al (2007) Blockade of MEK\/ERK signaling enhances sunitinib-induced growth inhibition and apoptosis of leukemia cells possessing activating mutations of the FLT3 gene. Leuk Res (epub ahead of print.)","DOI":"10.1016\/j.leukres.2007.09.017"},{"issue":"5","key":"56_CR21","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1158\/1535-7163.MCT-06-0814","volume":"6","author":"M Koyama","year":"2007","unstructured":"Koyama M, Matsuzaki Y, Yogosawa S et al (2007) ZD1839 induces p15INK4b and causes G1 arrest by inhibiting the mitogen activated protein kinase\/extracellular signal-regulated kinase pathway. Mol Cancer Ther 6(5):1579\u20131587. doi: 10.1158\/1535-7163.MCT-06-0814","journal-title":"Mol Cancer Ther"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-008-0056-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-008-0056-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-008-0056-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T16:28:59Z","timestamp":1559233739000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-008-0056-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5,26]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["56"],"URL":"https:\/\/doi.org\/10.1007\/s10549-008-0056-8","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,5,26]]}}}